Comparison
Omega-3 (DHA/EPA) vs Vinpocetine
Omega-3 (DHA/EPA)
Essential fatty acids critical for brain structure and function. DHA comprises ~40% of brain polyunsaturated fatty acids.
Vinpocetine
Semi-synthetic derivative of vincamine from periwinkle. Increases cerebral blood flow.
| Field | Omega-3 (DHA/EPA) | Vinpocetine |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–3000mg | 5–30mg |
| Half-life | 24h | 2h |
| Onset | — | — |
| Evidence | EVIDENCEA | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USBanned |
| PubMed refs | 5200 | 600 |
The comparison in plain English
Auto-generated from dataOmega-3 (DHA/EPA) and Vinpocetine are both in the neuroprotective category respectively. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function. Vinpocetine Semi-synthetic derivative of vincamine from periwinkle.
Bottom line
Omega-3 (DHA/EPA) (evidence A, safety 5/5) has a weaker evidence base than Vinpocetine (evidence B, safety 4/5). Omega-3 (DHA/EPA) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Omega-3 (DHA/EPA) if
Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.
Choose Vinpocetine if
Vinpocetine is the better fit when your goal aligns with its mechanism (Inhibits phosphodiesterase 1 (PDE1), increasing intracellular cGMP and producing vasodilation specifically in cerebral arterioles) and the dose range (5–30mg) suits your protocol. Half-life is 2h.